Compare Stocks: ACH, BDSX, INFU, and XGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACH Accendra Health	$0.93 -9.7%	$2.00	$0.89 ▼ $5.63	$79.21M	1.53	898,641 shs	3.87 million shs
BDSX Biodesix	$29.20 +1.4%	$24.36	$5.26 ▼ $31.31	$303.98M	0.6	104,630 shs	100,865 shs
INFU InfuSystem	$12.85 +3.0%	$11.25	$7.29 ▼ $13.15	$259.34M	1.5	164,703 shs	506,200 shs
XGN Exagen	$8.41 +6.9%	$6.37	$2.59 ▼ $12.23	$190.65M	2.1	226,191 shs	351,726 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACH Accendra Health	-9.65%	-13.03%	-29.23%	-71.19%	+93,059,900.00%
BDSX Biodesix	+1.35%	+8.27%	+14.33%	+73.71%	+370.21%
INFU InfuSystem	+2.96%	+5.76%	+5.41%	+36.41%	+31.39%
XGN Exagen	+6.86%	+19.63%	+13.19%	+85.24%	-8.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACH Accendra Health	$0.93 -9.7%	$2.00	$0.89 ▼ $5.63	$79.21M	1.53	898,641 shs	3.87 million shs
BDSX Biodesix	$29.20 +1.4%	$24.36	$5.26 ▼ $31.31	$303.98M	0.6	104,630 shs	100,865 shs
INFU InfuSystem	$12.85 +3.0%	$11.25	$7.29 ▼ $13.15	$259.34M	1.5	164,703 shs	506,200 shs
XGN Exagen	$8.41 +6.9%	$6.37	$2.59 ▼ $12.23	$190.65M	2.1	226,191 shs	351,726 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACH Accendra Health	-9.65%	-13.03%	-29.23%	-71.19%	+93,059,900.00%
BDSX Biodesix	+1.35%	+8.27%	+14.33%	+73.71%	+370.21%
INFU InfuSystem	+2.96%	+5.76%	+5.41%	+36.41%	+31.39%
XGN Exagen	+6.86%	+19.63%	+13.19%	+85.24%	-8.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACH Accendra Health	1.80	Reduce	$1.50	61.19% Upside
BDSX Biodesix	2.80	Moderate Buy	$31.33	7.31% Upside
INFU InfuSystem	2.75	Moderate Buy	$16.67	29.70% Upside
XGN Exagen	2.89	Moderate Buy	$9.63	14.45% Upside

Current Analyst Ratings Breakdown

Latest ACH, BDSX, INFU, and XGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	XGN Exagen	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
9/8/2026	BDSX Biodesix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	BDSX Biodesix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	ACH Accendra Health	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$4.50 ➝ $1.50
8/11/2026	ACH Accendra Health	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform ➝ Neutral	$1.50
8/11/2026	ACH Accendra Health	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50
8/10/2026	ACH Accendra Health	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$4.50 ➝ $1.50
8/10/2026	BDSX Biodesix	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$27.00 ➝ $35.00
8/7/2026	XGN Exagen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/6/2026	ACH Accendra Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	BDSX Biodesix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $27.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACH Accendra Health	$2.73B	0.03	$3.45 per share	0.27	($5.96) per share	-0.16
BDSX Biodesix	$88.50M	3.48	N/A	N/A	($0.31) per share	-94.19
INFU InfuSystem	$143.34M	1.81	$1.00 per share	12.79	$2.47 per share	5.20
XGN Exagen	$66.57M	3.06	N/A	N/A	$0.77 per share	10.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACH Accendra Health	-$1.10B	-$3.91	N/A	10.34	N/A	-11.41%	-4.02%	0.70%	N/A
BDSX Biodesix	-$35.26M	-$3.17	N/A	N/A	N/A	-26.97%	-788.19%	-30.33%	11/2/2026 (Estimated)
INFU InfuSystem	$870K	$0.41	214.20	41.45	N/A	1.12%	2.78%	1.41%	N/A
XGN Exagen	-$19.95M	-$0.81	N/A	N/A	N/A	-26.61%	-104.46%	-28.93%	11/3/2026 (Estimated)

Latest ACH, BDSX, INFU, and XGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ACH Accendra Health	-$0.13	-$0.19	-$0.06	-$1.16	N/A	$613.23 million
8/5/2026	Q2 2026	BDSX Biodesix	-$0.9018	-$0.71	+$0.1918	-$0.71	$26.03 million	$26.86 million
8/4/2026	Q2 2026	XGN Exagen	-$0.1914	-$0.13	+$0.0614	-$0.13	$17.80 million	$19.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACH Accendra Health	N/A	N/A	N/A	N/A	N/A
BDSX Biodesix	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACH Accendra Health	N/A	0.41	0.30
BDSX Biodesix	5.12	2.85	2.85
INFU InfuSystem	0.50	1.98	1.59
XGN Exagen	1.96	3.18	3.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACH Accendra Health	N/A
BDSX Biodesix	20.96%
INFU InfuSystem	71.13%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
ACH Accendra Health	2.29%
BDSX Biodesix	23.20%
INFU InfuSystem	10.80%
XGN Exagen	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACH Accendra Health	6,500	76.90 million	75.14 million	N/A
BDSX Biodesix	334	10.55 million	8.10 million	No Data
INFU InfuSystem	473	20.18 million	19.10 million	Optionable
XGN Exagen	220	24.23 million	21.71 million	Optionable

ACH, BDSX, INFU, and XGN Headlines

Recent News About These Companies

Exagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Review

September 16 at 4:00 AM | defenseworld.netD

Exagen (NASDAQ:XGN) Coverage Initiated at B. Riley Financial

September 13, 2026 | americanbankingnews.com

Exagen (NASDAQ:XGN) Now Covered by B. Riley Financial

September 11, 2026 | marketbeat.com

BlackRock Inc. Purchases Shares of 142,625 Exagen Inc. $XGN

September 7, 2026 | marketbeat.com

Man Group plc Takes $778,000 Position in Exagen Inc. $XGN

September 4, 2026 | marketbeat.com

Flputnam Investment Management Co. Acquires New Position in Exagen Inc. $XGN

August 31, 2026 | marketbeat.com

Exagen Inc. (NASDAQ:XGN) Given Average Rating of "Moderate Buy" by Brokerages

August 27, 2026 | marketbeat.com

Exagen (XGN) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

Exagen: The Path To Profitability Just Became More Credible

August 5, 2026 | seekingalpha.com

Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability

August 4, 2026 | finance.yahoo.com

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Exagen Inc. Reports Second Quarter 2026 Financial Results

August 4, 2026 | markets.businessinsider.com

Exagen reports record second-quarter 2026 revenue and raises full-year guidance

August 4, 2026 | msn.com

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2026 | zacks.com

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

August 4, 2026 | quiverquant.comQ

Exagen reports record Q2 revenue of $19.9 million

August 4, 2026 | quiverquant.comQ

Exagen Inc. to Participate in Upcoming Investor Conference

July 28, 2026 | globenewswire.com

Exagen: A Small Diagnostics Company Approaching An Inflection Point

July 23, 2026 | seekingalpha.com

Exagen to Announce Second Quarter Financial Results on August 4, 2026

July 21, 2026 | markets.businessinsider.com

Exagen Shareholders Approve Directors, Auditor and Pay Package

June 9, 2026 | tipranks.com

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

June 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACH, BDSX, INFU, and XGN Company Descriptions

Accendra Health NYSE:ACH

$0.93 -0.10 (-9.65%)

As of 09/18/2026 03:58 PM Eastern

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.

Biodesix NASDAQ:BDSX

$29.20 +0.39 (+1.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$30.55 +1.35 (+4.62%)

As of 09/18/2026 07:30 PM Eastern

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

InfuSystem NYSE:INFU

$12.85 +0.37 (+2.96%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.82 -0.03 (-0.19%)

As of 09/18/2026 07:30 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Exagen NASDAQ:XGN

$8.41 +0.54 (+6.86%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.41 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACH, BDSX, INFU, and XGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACH, BDSX, INFU, and XGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACH, BDSX, INFU, and XGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACH, BDSX, INFU, and XGN Company Descriptions

Accendra Health NYSE:ACH

Biodesix NASDAQ:BDSX

InfuSystem NYSE:INFU

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACH, BDSX, INFU, and XGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACH, BDSX, INFU, and XGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACH, BDSX, INFU, and XGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACH, BDSX, INFU, and XGN Company Descriptions

Accendra Health NYSE:ACH

Biodesix NASDAQ:BDSX

InfuSystem NYSE:INFU

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools